Financial Results
Q3/Q1-3 2022 Results
Fresenius with weak third quarter driven by ongoing challenging macroeconomic environment – FY/22 guidance revised – Charting a new course for Fresenius
-
Healthy organic sales growth and ongoing margin pressure
-
Fresenius Medical Care’s business development impacted by delayed effects from improvements in North American Services business in challenging environment
-
Fresenius Kabi with healthy sales growth and sequential improvement
-
Fresenius Helios with strong organic sales growth, solid EBIT in line with usual third quarter seasonality
-
Fresenius Vamed impacted by macroeconomic headwinds and COVID-19
Selected Key Figures Q1-3/2022
SALES
€ 30197 m
+ 4% 1
Q1-3/21: €27,554 m
EBIT 2
€ 2952 m
-10% 1
Q1-3/21: €3,086 m
NET INCOME 2, 3
€ 1284 m
-8% 1, 4
Q1-3/21: €1,346 m
EARNINGS PER SHARE 2, 3
€ 2.29 m
-10% 1
Q1-3/21: €2.41
1 In constant currency
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
4 Excluding Ivenix acquisition
Sales by business segment
| € in millions | Q1-3/22 | Q1-3/21 | Change | Growth at constant rates | Organic growth | Acquisitions | Divestitures | % of total sales1 |
|---|---|---|---|---|---|---|---|---|
Fresenius Medical Care | 14,401 | 12,972 | 15% | 2% | 1% | 1% | 0% | 47% |
Fresenius Kabi | 5,814 | 5,370 | 8% | 2% | 2% | 0% | 0% | 19% |
Fresenius Helios | 8,685 | 8,009 | 8% | 8% | 6% | 2% | 0% | 29% |
Fresenius Vamed | 1,647 | 1,549 | 6% | 6% | 6% | 1% | -1% | 5% |
Total | 30,197 | 27,554 | 10% | 4% | 3% | 1% | 0% | 100% |
-
1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.